Omisirge is approved for patients who receive cord blood transplantation following myeloablative therapy.
Gamida’s Long Regulatory Road Ends in Approval of Blood Cancer Cell Therapy Read More »
Coeptis Therapeutics Holdings, Inc. announced it has entered into a binding term sheet with Deverra Therapeutics, Inc. (“Deverra Therapeutics”) pursuant to which it has obtained an exclusive right, until August 31, 2023.
Palatin Technologies, Inc. today announced The International Journal of Molecular Sciences published a manuscript, “Stimulating the Melanocortin System in Uveitis and Diabetes Preserves the Structure and Anti-Inflammatory Activity of the Retina” by Tat Fong Ng and Andrew W. Taylor from Department of Ophthalmology, Boston University Chobanian and Avedisian School of Medicine, in Boston, Massachusetts.
A unanimous FDA committee vote supported the favorable risk-benefit profile of Innoviva’s sulbactam-durlobactam for hospital-acquired A. baumannii infections.
FDA Adcomm Backs Innoviva’s Pneumonia Antibiotic Read More »
En este Short os contamos el concepto teórico de los agujeros blancos. …
A la participación de la industria española en la misión espacial JUICE, se le suma la académica, a la cual dedicamos este segundo artículo de la serie. El Instituto de Astrofísica de Andalucía (IAA), adscrito al Consejo Superior de Investiga …
La participación española en la misión espacial JUICE (2) Read More »
Cultivarium and ATCC have entered a multi-phase research collaboration to expand the use of non-model microorganisms.
HuidaGene Therapeutics announces that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved its investigational new drug (IND) application for the planned multi-regional, multi-national clinical trial of HG004.
Phio Pharmaceuticals Corp. today announced that in vivo data from a mouse model of colon cancer demonstrates target synergy-enhanced anti-tumor efficacy from a novel dual-targeting mouse PD-1 and CTLA-4 of an INTASYL coformulation.
Ampio Pharmaceuticals, Inc. released the following letter to stockholders from its Chairman, Kevin Buchi and Chief Executive Officer, Mike Martino.
Ampio Pharmaceuticals Issues Letter to Stockholders – April 18, 2023 Read More »
